医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CAMBRIDGE, Mass.

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the appointment of industry veteran Paul Rasmussen as Regional Vice President, Asia Pacific and Japan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005036/en/

Paul Rasmussen, Regional Vice President, Asia Pacific and Japan, Vizgen (Photo: Business Wire)

“With the addition of Paul to our global team, Vizgen is well positioned to meet the growing demand for our market-leading MERSCOPE™ spatial genomics platform and open access datasets,” said Terry Lo, President and CEO of Vizgen. “Paul’s proven track record in driving product and service adoption regionally speaks for itself and with the addition of our stellar group of partners, we are empowering scientists with a new lens to interpret research, which will ultimately impact human health.”

A recognized Asia Pacific sales leader, Mr. Rasmussen was employed by NanoString Technologies for 13 years in a variety of roles. He most recently served as Director of APAC Life Sciences Operations. He previously worked at Applied Biosystems for 8 years. Mr. Rasmussen will be based in Singapore.

“This is a tremendously exciting time of growth for Vizgen, and I am thrilled for the opportunity to play a key role in leading their continued global expansion,” said Mr. Rasmussen. “Scientists are just beginning to realize the potential of spatial genomics and I look forward to working with Vizgen and playing a role in making spatial genomics a mainstay of laboratories everywhere.”

About Vizgen
Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company’s MERSCOPE™ Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com. For more information, go to www.vizgen.com. Connect on social media Twitter, LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005036/en/